您当前的位置：
首页 >
文章列表页 >
Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer
更新时间：2025-11-10

    • Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer

    • “According to the latest research, the first-line treatment of metastatic pancreatic cancer with irinotecan liposome combination scheme is not economical, which provides new ideas for the treatment of pancreatic cancer.”
    • ZHONGGUO YAOFANG   Vol. 36, Issue 21, Pages: 2681-2686(2025)

    • DOI：10.6039/j.issn.1001-0408.2025.21.11    

      CLC： R956;R979.1

    • Received：20 May 2025，

      Revised：2025-08-29，

      Accepted：29 August 2025，

      Published：15 November 2025

    移动端阅览

  • GAO Han,HU Dongxue,JIA Caifeng,et al.Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer[J].ZHONGGUO YAOFANG,2025,36(21):2681-2686. DOI： 10.6039/j.issn.1001-0408.2025.21.11.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer
Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer
Pharmacoeconomic evaluation of finerenone combined with standard regimen in the treatment of heart failure with preserved or mildly reduced ejection fraction
Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

Related Author

HUO Liman
DUAN Yangyang
LIANG Ping
SHAN Bin
SUN Xiaoli
FENG Rui
GAO Chuan
DONG Juanni

Related Institution

School of Health Emergency Management， Tianjin University
School of Pharmacy， Hebei Medical University
Clinical Pharmaceutics Room， the First Affiliated Hospital of Xi’an Medical University
Dept. of Oncology， the First Affiliated Hospital of Xi’an Medical University
Hebei Society for Integrated Drug and Health Technology Assessment
0